March 13–14, 2018 Hotel Kabuki, San Francisco, CA PRE-CONFERENCE WORKSHOP DAY March 12, 2018 NASA Ames Research Center Mountain View, CA

HARNESSING THE POWER OF BIG DATA IN PRECISION MEDICINE

Bought to you by: In conjunction with:

http://www.terrapinn.com/biodatawest OUR STORY

Atul Butte Director, Institute for In 2017, we held the inaugural BioData West, with an incredible speaker faculty transferring bleeding edge Computational Health technology into pharmaceutical development and healthcare. The event featured presentations from the Sciences, AI likes of Jeff Dean, Senior Fellow, Google - Google’s 20th employee and co-founder at Google Brain, Atul University of California, Butte, Director, Institute for Computational Health Science, UCSF and John Mattison, the Chief Medical San Francisco Information Officer and Assistant Medical Director for Kaiser Permanente.

PRECISION The revolutionary AI stream of the event was initially commissioned by Merck in order to implement a global MEDICINE AI strategy and live-streamed to their executive board. This year we are working alongside Roche to drive game changing technologies in drug development and healthcare.

HEALTH We are pleased to announce a partnership with NASA for 2018. Due to a federal partnership seeded between NASA and the NCI (National Cancer Institute) along with a pre-conference workshop taking SYSTEMS place at NASA on March 12th. These sessions are designed to bring together the world’s thought leaders and learn about new sources of data and collaboration with an open mind. Vikram Bajaj Co- Founder, Google James Dzierzanowski Life Sciences, Former Our partners include Roche, American Heart Association, GSK, NCI, NASA, Google, Merck, CLSA, UCSF Executive Director, CSO, GRAIL, Managing Kaiser Permanente and D-Wave amongst others. Director, Foresite Capital Management On March 13th and 14th we will focus on three streams that will inject new technologies into your industry: CLOUD COMPUTING 1. Artificial Intelligence “It was greatly appreciated by every single attendee I spoke with. And big for Merck, as it opened the org’s 2. Genomics and Health eyes in ways I was hoping” 3. Precision Medicine Mathai Mammen, Global Head of R&D, J&J DIGITAL HEALTH Register to hear from over 150 speakers from the leading pharma, biotech, healthcare and tech experts.

See you in San Francisco! Greg Corrado Co-founder, Google Brain Edward Glanville Michael Shackil Project Director Business Development Manager Terrapinn Terrapinn Naveen Jain QUANTUM [email protected] [email protected] Founder & CEO, +1 646 619 1773 +1 646 619 1809 VIOME COMPUTING

http://www.terrapinn.com/biodatawest 2018 SPEAKERS 150+ SPEAKERS INCLUDING Pharma/ Biotech:

Slava Akmaev Mark DePristo Manuel Corpas Riccardo Sabatini Iraneus Ogu Yaron Mazor Martin Akerman Thomas Clozel Senior Vice President & Head of deep learning Scientific Lead Co-Founder, Chief Data Africa AI, Blockchain and Senior VP, Technology CTO Co-Founder Chief Analytics Officer for genetics and Repositive Officer Longevity Lifemap Sciences Envisagenics Owkin BERG genomics Orionis Insilico Medicine Google Inc

Alex Zhavoronkov Aubrey de Grey Mathew Pletcher Shanrong Zhao Martin Sjoholm Govinda Bhisetti Megan Doerr Morten Sogaard (CSO, The Chief Science Officer Head of Rare Disease Director, Computational Senior Enterprise Head of Computational Principal Scientist Vice President and Biogerontology and Co-Founder Discovery Biology and Architect Chemistry Sage Bionetworks Head, Genome Sciences Research Foundation) SENS Foundation Roche Bioinformatics, Bayer Biogen & Technologies, CEO Worldwide R&D Worldwide R&D InSilico Medicine Inc Pfizer Pfizer

Greg Corrado Matthew Nelson Verner De Biasi Karen Hurst Nadeem Sarwar Karim Galil Steve Gullans Lara Mangravite Co-founder Head of Genetics Head Emerging Chief Innovation Officer President AiM Institute CEO Managing Director, President Google Brain GSK Platforms and Cyber Security Eisai Mendel Health Excel Ventures, Sage GSK Analyst CEO, Gemphire Moonshot Projects

Vikram Bajaj Naveen Jain Kristen Fortney Attila Csordas Chris Boone Preston Estep David Milward Chris Gibson Co- Founder, Google Founder & CEO CEO Founder Vice President, Real CSO Chief Technology Co-Founder and CEO Life Sciences, Former Viome BioAge Labs AgeCurve Limited World Data and Veritas Genetics Officer (CTO) Recursion CSO, GRAIL, Managing Analytics Linguamatics Director, Forsythe Pfizer Capital

Munther Baara Mauricio Carneiro Arnaud Desfeu Gunaretnam Mathai Mammen Abraham Heifets Chris Probert Gregory Bailey Head of New Clinical Head of Scientific Founder (Guna) Rajagopal Global Head of R&D CEO Founder Co-founder & partner Paradigm Software omicX VP - Global Head, Janssen Atomwise Elastic Genomics (in Mediqventures Pfizer Verily (Google Life Computational Sciences, Pharmaceutical stealth mode) Sciences) Discovery Sciences Companies of Janssen, Johnson & Johnson Pharmaceutical Companies of Johnson and Johnson

Adrien Rousset Prasun Mishra John Martinis Yasaman Mark Fingerhuth Andrew Stewart Peter Wittek Handol Kim Innovation Manager Founder and CEO Lead for Google’s Soudagar CEO and Founder CEO and Founder Chief, Quantum Machine General Manager, Amgen Agility Quantum Computing CEO and Founder ProteinQure Inc Autism Diagnostics Learning Quadrant Machine Pharmaceuticals Google Neurescence Inc Creative Destruction Learning Business Unit CEO D-Wave Systems, Inc American Association for Precision Medicine

WANT TO JOIN THIS SPEAKER LIST? Contact Michael Shackil now at +1 646 619 1809 Government/Non Profit: Jean Claude Sylvain Costes Ronald Elizabeth Baca Michael Sekora Sara Radcliff Mintu Turakhia Amy Pienta Zenklusen Lead scientist for Przygodzki Senior Health Advisor Ex Director, Socrates President and Chief Executive Director, Associate Research Director, The Cancer GeneLab Director, Genomic Governor’s Office of Project Executive Officer Center for Digital Scientist, Director, Data Genome Atlas, Centre NASA Medicine Planning and Research White House under California Life Health, Stanford Acquisitions, Director, for Cancer Genomics, Implementation State of California Ronald Reagan Sciences Association Director, Cardiac National AIDS & HIV Office of the Director VA Governor’s Office Electrophysiology, Data Archive Program National Cancer of Planning and Palo Alto VA ICPSR Research Institute

Jennifer Hall Christina Waters Chris Riley Patrick Wayte Duygu Tosun- Ian Dunham Julie Waters Kay Firth- President President & Chief Research Mgr - Institute SVP, Center for Turgut Scientific Director, Open Founder Butterfield American Heart Executive Officer for Precision CV Health Technology & Assistant Professor Targets Raremark Head Artificial Association R.A.R.E. Science Medicine Innovation and Co-Director of the EMBL-EBI Intelligence and American Heart American Heart Center for Imaging of Machine Learning Association Association Neurodegenerative World Economic Diseases (CIND) Forum San Francisco Veterans Affairs Medical Center Health System: Robert Burton Adam Berger Andreas Kogelnik Benson Hsu Scott Brandon Nazneen Aziz James Jim Broach Founder and CEO Senior Fellow, President and Founder Chief Medical Analytics Executive Director Executive Director Dzierzanowski Director of the Penn Center for Genomic Department of Health Open Medicine Officer Open Med Access Kaiser Permanente Executive Director State Institute for Interpretation and Human Service Institute Sanford Health Research Bank Kaiser Permanente Personalized Medicine, FDA University of Pennsylvania School

Noel Burt Ashley Winslow Amit Rastogi Catherine Kullo Iftikhar John Weinstein Pravin Mishra David Smith Program Manager Sr. Director, SVP for Strategy, Brownstein Professor Professor and Chairman Director, Precision Professor of Laboratory Broad Institute Translational Growth and Innovation Scientific Director Mayo Clinic for Department of Genomics Core Medicine and Research & Portfolio Inova Health System Manton Center for Bioinformatics and Laboratory & R&D Pathology Chairman Development, Orphan Orphan Disease Computational Biology Intermountain of the Technology Disease Center Research MD Anderson Cancer Healthcare Assessment Group University of Center Center for Individualized Pennsylvania Medicine Mayo Clinic

James Mills Anna Berry Katie (Lintner) Westyn Branch- Matthew Trunell Vipul Kashyap Ron Dixon Paul Avillach Barbeau Scientific Director of Miller Elliman Chief Information Chief Enterprise Medical Director Assistant Professor Assoc. Professor, Brown Personalized Medicine IT Project Scientist Instructor in Medicine Officer & VP of IT Information Architect Massachusetts Harvard Medical University Alpert and Medical Director of Nationwide Harvard Medical Fred Hutch Cancer Northwell Health General Hospital School & i2b2 Medical School, Director Molecular Diagnostics Children’s Hospital School Research Centre tranSMART of Laboratory Medicine Swedish Cancer Foundation Lifespan Academic Institute Medical Center

Academic: Russ Waitman Rudy Potenzone Peter Goodhand Alysson Muotri Samuel “Sandy” Elia Stupka Atul Butte Benedict Paten Director of Medical Vice President President Professor, Director of Aronson Senior Director, Director, Institute for Director of Data Informatics i2b2 tranSMART Ontario Institute the Stem Cell Program Executive Director IT Data Science and Computational Health Management University of Kansas Foundation for Cancer Research Institute for Genomic Partners Bioinformatics Sciences UCSC Medical Center & (OICR) Medicine, Rady Personalized Dana-Farber Cancer University of i2b2 tranSMART Executive Director Children’s Hospital Medicine Institute California, San Foundation Global Alliance for Sanford Consortium Francisco Genomics and Health (GA4GH)

Olivier Elemento Gordon Okimoto Ali Torkamani Sergio Baranzini Gerald Higgins Olexandr Isayev Vikash Veronica Weiner Associate Professor, Co-Director Director of Genome Professor Research Professor of Professor Mansinghka CEO and Co-Founder Head, Laboratory University of Hawaii Informatics, Drug UCSF Computational Medicine University Of North Principal Investigator, Resiliance of Cancer Systems Cancer Center Discovery, Integrative and Bioinformatics, Carolina MIT Probabilistic Therapeutics Biology, Director, Structural & University of Computing Project Director of Special Englander Institute Computational Biology Michigan Medical MIT Projects for Precision The Scripps School MIT Probabilistic Medicine, Associate Translational Science Computing Project Director, Institute Institute for Computational Biomedicine, Cornell Lead for the largest-scale cancer First man to conduct genomic Bringing AI and microbiome Producer of the world’s largest genomics project to date experiments in space together for the first time cardiac dataset

Jean Claude Zenklusen Mintu Turakhia Director, The Cancer Genome Atlas, Centre for Cancer Sylvain Costes Naveen Jain Executive Director, Center for Digital Health, Genomics, Office of the Director Lead scientist for GeneLab Founder & CEO Stanford, Director, Cardiac Electrophysiology, National Cancer Institute NASA Viome Palo Alto VA

Collating DNA and health data from The brains behind the Reagan 1 million Veterans GAME administration’s “Star Wars” initiative

Ronald Przygodzki Michael Sekora Director, Genomic Medicine Implementation CHANGERS Ex Director, Socrates Project VA White House under Ronald Reagan

Rare Diseases - Bringing big data Founder of the world’s most Developed a first-of-its-kind quantum- Co-founder of Google’s large scale and genomics to unlock cures watched genomics start-up enabled molecular comparison application deep neural networks project

Atul Butte Vikram Bajaj Govinda Bhisetti Greg Corrado Director, Institute for Computational Health Sciences Co- Founder, Google Life Sciences, Former CSO, Head of Computational Chemistry Co-founder University of California, San Francisco GRAIL,Managing Director, Foresite Capital Biogen Google Brain PHARMA

Matthew Nelson Head of Genetics GSK

The genetics of drug efficacy: Opportunities and challenges Fuelling R&D productivity & innovation with AI

Mark DePristo Morten Sogaard Head of Deep Learning Vice President and Head, for Genetics and Genomics Genome Sciences & Brain Genomics and machine learning- How to get a deep dive into the Google Inc Technologies, Worldwide R&D world of brain genomics using AI? Pfizer • How Pfizer uses advanced analytics and AI to drive forwards pharmaceutical development • Use cases ranging from business process engineering and automation to insights from healthcare data and genomics • What are the key obstacles to AI implementation? Mathew Pletcher Head of Rare Disease Discovery Roche Rare Diseases in Precision Medicine

Nadeem Sarwar President AiM Institute Eisai Establishing modern enterprise architecture in a pharmaceutical R&D Understanding the power of Quantum Computing in Drug Discovery division

Govinda Bhisetti Head of Computational • Using Quantum computing to transform traditional R&D Chris Boone Chemistry drug discovery processes, improve speed and productivity Vice President, Real alongside significantly reducing costs and accelerating World Data and PANEL: Where does emerging technology such as AI, precision Biogen Analytics access to new therapies for patients Pfizer medicine and next generation diagnostics fit into a health system- • Unveiling a first-of-its-kind quantum-enabled molecular What is the value? Where is the evidence? How do you persuade us to comparison application that could significantly improve implement? advanced molecular design to speed up drug discovery for complex neurological conditions • Solving complex business problems millions of times faster than classical computing by leveraging the properties of Verner De Biasi Head Emerging quantum physics in computing Platforms GSK Understanding the new blockchain ecosystem - empowering research and data democratization in a secure manner HEALTHCARE

John Weinstein Professor and Chairman AI - The Ethical Debate for Department of Bioinformatics and Computational Biology New analytical tools for OMICS How to get the best out of your data! MD Anderson Cancer Center James Dzierzanowski • With unprecedented data sharing via the cloud we have been provided with vast Executive Director data lakes at our fingertips Kaiser Permanente • Harnessing meaning from this data is possible through AI • However, as AI advances we are unable to always disseminate why or how it has Pravin Mishra deduced meaning from the data Director, Precision Genomics Core • With garbage in garbage out does AI become biased? Laboratory & R&D Intermountain Intermountain Precision Genomics for Everyday Patients Healthcare

Nazneen Aziz Executive Director Developing the Inova Precision Medicine Roadmap: Convergence of implementation science, precision Kaiser Permanente Research Bank medicine, and the learning healthcare system Biobanks - propelling precision medicine into the clinic in the fastest way possible

Amit Rastogi • What are the challenges faced when implementing a system wide precision SVP for Strategy, Growth and Innovation medicine platform across a healthcare system? Inova Health System • Developing a harmonized roadmap for the implementation of precision medicine- David Smith Real world case studies on implementation of precision medicine at Inova Professor of Laboratory • What were the financial implications and how can the model benefit your Medicine and Pathology Chairman precision medicine implementation strategy? of the Technology Using different whole genome sequencing platforms to characterize • Collaborations and partnerships with vendors to make the process work How to Assessment Group cancer genomes and their clinical impact make it a success story through developing early stage frameworks? Center for Individualized Medicine Mayo Clinic

Anna Berry Scientific Director of Personalized Medicine and Medical Director of Molecular Diagnostics Integrating gene panels and EMR records to develop treatment Swedish Cancer pathways and cancer cure frameworks on large scales Where does emerging technology such as AI, precision medicine and next generation diagnostics fit into a Institute health system- What is the value? Where is the evidence? How do you persuade us to implement?

Benson Hsu Vipul Kashyap Matthew Trunell Lara Mangravite Chief Medical Analytics Chief Enterprise Chief Information Officer & President Officer Information Architect VP of IT Sage Sanford Health Northwell Health at Fred Hutch Cancer Research Centre Electronic Consent - How to develop an electronic e-trial strategy effectively? TECHNOLOGY

Next Generation Diagnostics Deep Neural Networks – AI Drug Discovery

Vikram Bajaj Greg Corrado Govinda Bhisetti Co- Founder, Google Life Co-founder Head of Computational Sciences, Former CSO, Google Brain Chemistry GRAIL, Managing Director, Biogen Foresite Capital

Blockchain Quantum Computing Microgravity Biology

Munther Baara Handol Kim Sylvain Costes Head of New Clinical General Manager, Lead scientist for Paradigm Quadrant Machine GeneLab Pfizer Learning Business Unit NASA D-Wave Systems, Inc GOVERNMENT & NON-PROFIT

Jennifer Hall President American Heart Association Collaboration: How to enable researchers to use data and collaborate easier?

Developing an ecosystem in which EHR and genomic data can flow freely Elizabeth Baca Senior Health Advisor Governor’s Office of Planning and Research State of California California’s Initiative to advance Precision Medicine from the bench to Governor’s Office the bedside Ronald Przygodzki of Planning and Director, Genomic Medicine Research Implementation • Elements of MVP (Million Veterans Program): The direction for the future, and strategies to transform genomic efforts into VA the clinic Sara Radcliff • Building one of the world’s largest medical databases by President and Chief safely collecting blood samples and health information from Executive Officer California Life one million Veteran volunteers Sciences Association CLSA California: Partnering and driving a hot bed of translational • How to manipulate one of the largest genomic data sets in medicine in California the world • Future use of MVP data to enhance the health of veterans

Christina Waters President & Chief Executive Officer R.A.R.E. Science Developing translational medicine through the three main pillars: benchside, bedside and community

Michael Sekora Ex Director, Socrates Developing trials of the future Project White House under Ronald Reagan The next evolutionary leap of technology exploitation- unprecedented speed, efficiency and agility

Pre-conference Workshop Mintu Turakhia Executive Director, Ian Dunham Center for Digital Health, Scientific Director, Open Stanford • How wearables are changing patient centeredness and Targets Director, Cardiac compliance for clinical trials EMBL-EBI DATATHON ON OPEN TARGETS Electrophysiology, • Digital Biomarkers and Digital Therapeutics: See how Palo Alto VA digitalization leads to better efficiency and insights • Developing large wearables trials - the lessons learned from Pre-conference Workshop building arrhythmia data sets through wearables Julie Waters Founder Raremark

What would patients say if you asked them? PRE-CONFERENCE WORKSHOP

NASA AMES OPEN SOURCE 10:30 PANEL: Integrating data sets across communities Collaborative Scientific Innovation & • How tranSMART and I2B2 are connecting communities AHA Precision Medicine Platform Hands-on Workshop Translational Medicine Stream • Case studies on tranSMART and its benefits • How can you integrate tranSMART into your industry? 08:45 MORNING BRIEFING: This workshop looks to introduce the AHA Precision Medicine Platform Chair: Rudy Potenzone, Vice President, i2b2 tranSMART Foundation Keith Elliston, CEO, i2b2 tranSMART Foundation The next evolutionary leap of technology exploitation- that has been developed to encourage open sourced collaboration unprecedented speed, efficiency and agility and ease of access and sharing of data. You will be guided through the Preston Estep, CSO, Veritas Genetics course through two instructors who will provide hands on education • Why have present process improvements in technology Paul Avillach, Assistant Professor, Harvard Medical School & i2b2 into how to use the platform and get you up and running in no time. tranSMART Foundation exploitation only addressed peripheral aspects of the process - sociological, psychological, and financial - and therefore at best American Heart Association Russ Waitman, Director of Medical Informatics, University of Kansas Instructors TBC Medical Center & i2b2 tranSMART Foundation only had a minor positive impact? • How does the automated innovation revolution enable us to address technology exploitation directly? 11:00 Cross ecosystem collaboration for Precision Medicine • How the Automated Innovation Process developed in the U.S. • How will intelligent formularies with tiers based on cohorts of intelligence community and was used on highest priority White genomic profiles, adherence characteristics and EHR records will House initiatives including: Stealth, Star Wars, resurrection of the change health systems? U.S. IC industry, advanced materials and the dismemberment of the • Integrated and cross-matched data from claims, EMR combined Soviet Union with pre-approval safety and efficacy data and post marketing Michael Sekora, Ex Director, Socrates Project, White House under Ronald surveys to better stratify the patient population into subgroups Reagan to design specific interventions including but not limited to: Modification of Formulation, Companion Diagnostics, supplementary drugs to ameliorate side effects, Medication 09:15 KEYNOTE: Adherence Reminders, Education How Google’s quantum computing efforts could change the • How could interventions in the context of a targeted Phase world IV trials be used to negotiate agreements on drug pricing and • Understand exactly where we are in the efforts to build a formulary placement? quantum computer? • Hype or Reality- What are the true capabilities of quantum Vipul Kashyap, Chief Enterprise Information Architect, Northwell Health computing • Should we be worried about quantum computing as a threat to 11:20 Open source collaboration and the cloud- Building next blockchain? generation infrastructure for the world’s researchers John Martinis, Lead for Google’s Quantum Computing, Google • Understanding the power of the cloud infrastructure to bolster collaboration efforts 10:00 Blockchain Disruption & Data Donation: How Blockchain Will • How to transfer from latent infrastructure into the cloud Change Our Industry • Sharing data lakes - where we are and what we have to do to progress • Developing a smart-contract between patient and healthcare stakeholders that makes it easy to aggregate health data in a Benedict Paten, Director of Data Management, UCSC secure, trusted, automated, and error-free way to enforce rules, privacy, and regulations in a mutually agreed upon manner 11:40 How open source platforms and collaboration are changing • Enabling patients to aggregate their data from diverse health the work carries out between NASA and NCI? sources and share what they choose to with their physicians and • What are the advantages of partnerships researchers • Discussing different partnering models • Putting the patient in control of their health and well-being, • Understanding how to share data in a fair manner rather than being along for the ride NASA & NCI Munther Baara, Head, New Clinical Paradigm, Pfizer 12:00 Lunch

http://www.terrapinn.com/biodatawest http://www.terrapinn.com/biodatawest PRE-CONFERENCE WORKSHOP

Collaborative Scientific Innovation & Translational Medicine 2:40 Precision FDA- Taking Genomic Testing to the Next Level Part 2 continued Hackathon GSK Open Targets Stream • How the FDA is creating a modern, flexible and dynamic regulatory system for NGS 1:00 Cardio Genomics eXchange commons (CGX): A cloud-based DATATHON ON OPEN TARGETS: In partnership with EMBL- EBI • Ways to develop these standards, which can be used by test collaboration platform for the analysis and exchange of and Sanger Institute developers to ensure their tests produce accurate and reliable genome sequencing data results Part 1: Educating on the open targets platform • How the aggregation of clinical information in curated databases • Development of a ‘Genome Dashboard’ that allows users to Open Targets is an innovative, large-scale, multi-year, public-private partnership will create a “data commons” that will serve as a reliable source of interactively explore genome sequencing data and identify disease- that uses human genetics and genomics data for systematic drug target scientific evidence that test developers could use to demonstrate causing variants in individuals with cardiovascular disease (CVD). identification and prioritisation. that NGS test results are relevant to a person’s disease or • Integrating informatics resources that provide information about Visit the Open Targets Platform which provides an integration of public domain outcome the clinical interpretation of specific genomic findings previously data to enable target identification and prioritisation. Adam Berger, Senior Fellow at the Department of Health and Human Services, reported in humans? Generating and interpreting the data required to identify a good drug target FDA • How to merge Genome Dashboard into the cloud-based American demands a diverse set of skills, backgrounds, evidence types and technologies, Heart Association Precision Medicine Platform to create a genomics which do not exist today in any single entity. Open Targets brings together 3:10 platform called CardioGenomics eXchange commons (CGX). expertise from four complementary institutions to systematically identify and PANEL: • Creating a cloud-based data commons where researchers can prioritise targets from which safe and effective medicines can be developed. Investing in healthcare- What you need to be successful with a VC collaboratively analyze and share genomic data from CVD patients • What do pharmaceutical companies and VC’s want to invest in? to advance precision medicine initiatives and accelerate genetic Our goals are to: • How are we seeing digital investments paying off across pharma findings associated with heart disease • Systematically find the best targets to safely & effectively treat and healthcare? Katie (Lintner) Miller, IT Project Scientist, Nationwide Children’s Hospital disease • What factors are required to gain successful investment from • Help others find good targets pharmaceuticals? 1:20 A FAIR guide for data providers to maximise sharing of • Get those targets adopted into drug discovery pipelines Chair: Steve Gullans, Managing Director, Excel Ventures, CEO, Gemphire human genomic data Vikram Bajaj, Co- Founder, Google Life Sciences, Former CSO, GRAIL, We currently focus on oncology, immunology and neurodegeneration through an Managing Director, Foresite Capital Management • Data sharing is critical. For every sharing transaction, a successful R&D framework that can be applied to all aspects of human disease How treating data like a currency will increase sharing and enable Gregory Bailey, Co-Founder & Partner, Mediqventures ground breaking research in a FAIR manner? Peter Wittek, Chief Quantum Machine Learning, Creative Destruction • How providers of human genomic data fulfil their social contract Instructors and Leaders: with data donors when their shareable data conforms to FAIR Ian Dunham, Scientific Director, Open Targets, EMBL-EBI VC and Investors Showcase (Findable, Accessible, Interoperable, Reusable) principles. Matthew Nelson, Head of Genetics, GSK • Defining guidelines for data providers wishing to maximise their 3:50 SpliceCore: Drug Target Discovery with Splicing AI shared data’s FAIR-ness. Martin Akerman, CTO, Cofounder, Envisagenics Manuel Corpas, Scientific Lead, Repositive 4:00 Autism Diagnostics Technologies 1:40 PANEL: Pre-competitive collaboration Part 2: Advance module- Andrew Stewart, CEO and Founder, Autism Diagnostics • How to effectively partner with other industry members to Integrating your expertise and AI approaches into the Open Targets platform advance research whilst maintaining a competitive edge? 4:10 Mendel.AI • Case studies of operative frameworks and precompetitive Karim Galil, CEO and Founder, Mendel.AI collaboration between industry partners. • Technologies used to assist with pre-competitive collaboration 4:20 Elastic Genomics Chair: Nadeem Sarwar, President AiM Institute, Eisai Chris Probert, Founder, Elastic Genomics (in stealth mode) Mauricio Carneiro, Head of Scientific Software, Verily (Google Life Sciences) 4:30 Improve patient identification in cardiovascular by using Bertrand Bodson, Chief Digital Officer,Novartis machine learning – concrete case Gunaretnam (Guna) Rajagopal, VP - Global Head, Computational Sciences, Discovery Adrien Rousset, Innovation Manager, Amgen Sciences, Janssen, Pharmaceutical Companies of Johnson and Johnson 4:40 Neuroscence Inc 2:20 Leveraging private information retrieval techniques to Yasaman Soudagar, CEO and Founder, Neurescence Inc enable interrogation of protected genomic data • How to maintain genomic and e-health information animosity and 4:50 ProteinQure Inc security while stored, in transit, and in use. Mark Fingerhuth, CEO and Founder, ProteinQure Inc • How have advances in private information retrieval (PIR) opened doors for the use of protected data without the need to expose 5:40 Close the underlying information? • How will Homomorphic encryption and other PIR methods be best leveraged to enable multi-party genomic comparisons while http://www.terrapinn.com/biodatawest maintaining data privacy? Alexander Titus, Biomedical Data Scientist – B.Next/ In-Q-Tel CONFERENCE DAY 1 1/6 CONFERENCE DAY 1 2/6

TUESDAY, MARCH 13TH 2018 TUESDAY, MARCH 13TH 2018

OPENING KEYNOTE PLENARY ARTIFICIAL INTELLIGENCE GENOMICS AND HEALTH PRECISION MEDICINE SPONSORED AND CO-PRODUCED BY ROCHE 08:30 Chairman’s Opening Remarks Sequencing Populations Cancer Diagnostics AI in Drug Discovery and Development 08:40 J&J FUTURE VISION IN AI AND COMPUTATIONAL BIOLOGY 11:20 Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of Johnson & Johnson Developing “DAVE”: a simple way to Using different whole genome Rethinking predictive modelling in the visualize large datasets in the battle sequencing platforms to characterize age of AI against cancer cancer genomes and their clinical • How Numerate’s platform drives programs 09:00 Rare Diseases - Bringing big data and genomics to unlock cures • How new tools and platforms developed impact by following signals and unlocking low • the current state of the field and how have new techniques in data analytics allowed us to probe deeper into data sets to gain understanding of by the NCI are changing the paradigm of • How do we balance the equation of Speed: through-put / high content biology rare disease morphologies? data accessibility across the country Depth: Cost across genomic sequencing • Applying similar modeling techniques • How do we connect millions of disease specific data points using novel statistical machine learning techniques to develop new therapies? • How these tools allow us to keep up with options with publicly available data in order to • The time is now - how does UCSF leverage the power of supercomputing infrastructure, once reserved for astrophysicists, to develop new the exponential worldwide growth of • Covering Illumina and high throughput successfully model a vast number of pathways to cures? genomic datasets whole genome sequencing including sources of preclinical attrition (ADME and Atul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco • How to carry out complex analysis at the mate-pair sequencing tox) data source whilst allowing the user to • What is the impact of BGI’s proposed $100 • Why pharma and health systems need 09:20 PANEL: Where does emerging technology such as AI, Blockchain, Precision Medicine and next generation diagnostics fit into a explore the data and download the desired whole genome on the clinician and what is to start sharing data to guarantee the health system- What is the value? Where is the evidence? How do you persuade us to implement? facets the value add to preemptive care? success of predictive modelling • Is the clinic ready for the influx of new precision medicines? Jean Zenklusen, Director, The Cancer Genome David Smith, Professor of Laboratory Medicine Brandon Allgood, CTO and a cofounder, Atlas, Centre for Cancer Genomics, Office of the and Pathology Chairman of the Technology Numerate Inc • What are CIOs at large healthcare systems looking for to drive precision medicine into the clinic? Director, National Cancer Institute Assessment Group Center for Individualized • What value has been generated to health systems through precision medicine? Are we focusing on the right priorities? Medicine, Mayo Clinic James Dzierzanowski, Executive Director, Kaiser Permanente Matthew Trunell, Chief Information Officer & VP of IT, Fred Hutch Cancer Research Centre 11:40 New analytical tools for OMICS How to Integrating gene panels and EMR Augmenting Drug Discovery with Vipul Kashyap, Chief Enterprise Information Architect, Northwell Health get the best out of your data! records to develop treatment pathways Artificial Intelligence at Massive Scale and cancer cure frameworks on large Benson Hsu, Chief Medical Analytics Officer, Sanford Health • Tackling the new emerging field of • Bringing substantial improvements to the scales Vikram Bajaj, Co- Founder, Google Life Sciences, Former CSO, GRAIL, Managing Director, Foresite Capital Management integrating disparate omic data from efficiency of discovery and development genomics, proteomics andglycomics • What impacts will the expansion of the efforts through the expansion and Chris Boone, Vice President, Real World Data and Analytics, Pfizer Swedish Precision medicine program have acceleration of traditional approaches Gunaretnam (Guna) Rajagopal, VP - Global Head, Computational Sciences, Discovery Sciences, Janssen • Identifying the technical and biological barriers to omic integration, with on healthcare across the system? • How Recursion views the use of AI Adam Berger, Senior Fellow, Department of Health and Human Services, FDA solutions to build a consensus towards • Implementing new technologies - How in discovery and development – from data integration in bioscience and better we are implementing the roadmap for strategies to accelerate discovery and 10:00 TITLE SPONSORSHIP AVAILABLE defined phenotypes the delivery of next generation precision imaged-based phenotypic screening Do you have a solution you would like to share with our audience? • What is being done to facilitate the medicine into the Providence Health platforms System? Contact Michael Shackil now on: [email protected] or call at +1 646.619.1809 integration effort in an effective manner? • Overviews of internal successes in rare John Weinstein, Professor and Chairman for • What evidence is there for universal disease, immunology, and immuno- Department of Bioinformatics and Computational genetic testing of cancer patients and will oncology alongside partnerships with 10:20 Speed networking Biology, MD Anderson Cancer Center it bring the expected value? large pharmaceutical companies including 10:40 Morning Coffee Anna Berry, Scientific Director of Personalized Sanofi and Takeda Medicine and Medical Director of Molecular • Recursion’s 5-7 year vision to leverage Diagnostics, Swedish Cancer Institute technology and massive proprietary datasets to build a map of human cellular biology Chris Gibson, Co-Founder and CEO, Recursion

12:00 SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE Extracting precise biodata through the Do you have a solution you would like to Do you have a solution you would like to power of text mining share with our audience? share with our audience? • Empowering high-value knowledge Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. discovery and decision support [email protected] or call at [email protected] or call at • Improving risk stratification through the +1 646.619.1809 +1 646.619.1809 characterization of patient populations based on social determinant data • Supporting clinical document improvement through NLP David Milward, Chief Technology Officer (CTO), http://www.terrapinn.com/biodatawest Linguamatics CONFERENCE DAY 1 3/6 CONFERENCE DAY 1 4/6

TUESDAY, MARCH 13TH 2018 TUESDAY, MARCH 13TH 2018

INTERACTIVE ROUNDTABLES 2:40 Blockchain: how to make it work California’s Initiative to advance Novel CNS drug targets in the for emerging and less-developed Precision Medicine from the bench to regulome identified by deep learning 12:20 1. Integrating EMR: Integration of 2. Collaboration: How to enable 3. Quantum Computing: Where are we healthcare systems the bedside – • How to use domain expert knowledge- electronic medical records with a researchers to use data and and what we are doing? • Exploring options using blockchain to • Hear how the Governor of California’s driven deep learning of pharmaco- achieve better health data storage and interest and leadership in the field led to phenomic datasets to yield abundant biomedical knowledge network to collaborate easier? Chair: D- Wave (sponsored) applications statewide collaborative models to realize human CNS drug targets predict medical outcomes Chair: Christopher Riley, Research the potential of precision medicine Chair: Sergio Baranzini, Professor, UCSF Administration Manager, American Heart • Discussing clinical data access, exchange, • Moving beyond the known “reader, writer Association interoperability, privacy issues and • How the state established multi-sector and eraser” proteins: usingcomputational regulatory concerns collaborative teams to advance efforts in methodologies to identify more selective 4. CLSA California: Partnering and 5. Electronic Consent - How to 6. Personal genetic testing - What are • How applications for pharma focus on precision medicine candidates driving a hot bed of translational develop an electronic e-trial strategy the impacts and implications? aging and longevity research, which • Examples from the eight demonstration • Utilizing a spatial, longitudinal and medicine in California effectively? Chair: Westyn Branch-Elliman, Instructor in could enable Africa to make more original projects that range from heart disease to biomechanical dynamical analysis of the Chair: Sara Radcliff, President and Chief Chair: Megan Doerr, Principal Scientist, Sage Medicine, Harvard Medical School contributions to healthcare pediatric cancer output to reveal previously unknown Executive Officer, California Life Sciences Bionetworks • How optimizing processes for emerging Elizabeth Baca, Senior Health Advisor Governor’s network-based drug targets Association Sarah Meeder, Research Compliance Specialist, and less-developed healthcare systems Office of Planning and Research, State of Gerald Higgins, Research Professor of CUNY like in Africa could be helpful in the California Governor’s Office of Planning and Computational Medicine and Bioinformatics, acceleration of progress for more Research University of Michigan Medical School 7. Drug Discovery - Expediting the 8. Big Data and the CNS - using big 9. Stem cells & Rare Diseases - How developed healthcare systems Sara Radcliff, President and Chief Executive drug development through genomics, data datasets and approaches in the to develop an infrastructure in which Iraneus Ogu, Africa AI, Blockchain and Longevity, Officer, California Life Sciences Association structural and cultural changes development of medicines for CNS researchers can be connected with Insilico Medicine Chair: Nadeem Sarwar, President, AiM Institute, indications including NDDs and pain/ patients and tools to develop therapies migraine disorders Eisai 3:00 SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE High impact applications of AI in Chair: Michael Burczynski, Senior Director and Do you have a solution you would like to Do you have a solution you would like to pharma Head of Translational Biomarker Research, Early Stage Development, Teva share with our audience? share with our audience? Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. Richard Wendell, Founder and CEO, tellic [email protected] or call at [email protected] or call at LLC 10. Text mining and image recognition 11. Translational Medicine - 12. Federal Partnerships - How to work +1 646.619.1809 +1 646.619.1809 - Developing new tools Developing infrastructure for precision with federal bodies and gain access to Chair: Karim Galil, CEO, Mendel medicine data Sequencing And Omics Aging And Drug Development Multimodel Integration 1:00 Networking Lunch 3:20 Computational identification of isoform Developing new drug targets for aging Multimodel data analysis for single cell Blockchain Policy and Governance AI in Drug Discovery and Development switch and alternative splicing events through novel insilico methodologies multiuse data for immunotherapy in ZSF1 fa/faCP rats, a model of human • Aging has become a major risk factor for • Predictive biomarkers for ovarian and liver 2:20 Understanding the new blockchain Risk management for precision A computational cpproach for type 2 diabetes: How new isoform many diseases including cancer, diabetes, cancer developed through novel self- ecosystem - empowering research medicine and big biodata identifying synergistic drug technologies could transform research heart disease and dementia leaning algorithms to provide actionable and healthcare and data democratization in a secure • How to implement a risk mitigation combinations- fueling a new generation • Defining new tools for the applications of cures manner process amongst a complex healthcare of drug combinations to treat cancers • Identification of predictive biomarkers aging research and information technology • How to translate an equation into a cure in of disease progression using isoform • Improve drug traceability between drug system • Identification of the right combinations • Empowering new business models, less than a year using new algorithms level sequencing- what are the potential manufacturers, wholesalers, pharmacists • Essential parts of the risk management through trial and error, a labor and resource regulation, comprehensive and integrated • Predicting response to blockade to specific implications for the clinic? and patients through tracking and program and case studies on they were intensive process whose scale quickly set of aging biomarkers immune checkpoint genes verification of secure product information escalates as more drugs can be combined • Why are we not moving to isoform level implemented at Lifespan • New engagements with large • Multimodel data analysis for biomarker resolution that could provide us with real • Improving authentication of health records • What are the advantages of systematic • Engaging in the development of a broad pharmaceutical companies and investors discovery and protocols on record sharing frameworks to identifying, assessing, and computational approach for predicting biological insights? to fully drive the field forwards Gordon Okimoto, Co-Director, University of • Empowering clinical trials where altering addressing risks in the implementation of synergistic combinations using easily • With a greater understanding of isoform Alex Zhavoronkov, (CSO, The Biogerontology Hawaii Cancer Center obtainable single drug efficacy. switching we can remove the chance or modifying data from clinical trials precision medicine? Research Foundation) CEO, InSilico Medicine Inc of false signals for cancer states - how fraudulently can be eradicated James Mills Barbeau, MD, JD, Director of • How does this allow you to forego a • Precision medicine - where patients, Laboratory Medicine, Brown University/Lifespan detailed mechanistic understanding significant is isoform level sequencing in researchers and providers can collaborate Academic Medical Center of drug function, and limited drug removing signal noise? to develop individualised care combination testing? Shanrong Zhao, Director, Computational Biology and Bioinformatics, Worldwide R&D, Pfizer Verner De Biasi, Head Emerging Platforms, GSK • Why is this method impactful for identification of drug synergy to drive new effective cancer cures into the clinic? Olivier Elemento, Associate Professor, Head, Laboratory of Cancer Systems Biology, Director, Englander Institute for Precision http://www.terrapinn.com/biodatawest Medicine, Associate Director, Institute for Computational Biomedicine, Cornell CONFERENCE DAY 1 5/6 CONFERENCE DAY 1 6/6

TUESDAY, MARCH 13TH 2018 TUESDAY, MARCH 13TH 2018

3:40 Systems biology approaches to Molecular signatures of human Fuelling R&D productivity & innovation 5:30 PANEL: Establishing modern enterprise architecture in a Pharmaceutical R&D division determine the cell-specific gene mortality: Biomarkers and therapies with AI • Scale your R&D pipeline whilst enabling innovation regulatory potential of genetic • Accelerating drug testing by developing • How Pfizer uses advanced analytics • How to enable speed and agility alongside increasing business and IT efficiency and effectively associations in complex diseases molecular signatures of mortality and AI to drive forwards pharmaceutical • Case study: How implementation efforts within IT infrastructure empower researchers • Genetic association studies identify risk • Attaining the best signatures by deeply development Chair: Martin Sjoholm, Senior Enterprise Architect, Bayer DNA variants but fall short of providing a phenotyping large human cohorts • Use cases ranging from business process biological context Bertrand Bodson, Chief Digital Officer, Novartis • High-throughput omics data, coupled with engineering and automation to insights • How UCSFe integrated GWAS data with innovative machine learning, is revealing from healthcare data and genomics 6:00 regulatory information from ENCODE and new biomarkers and drug targets • What are the key obstacles to AI PANEL: AI - The Ethical Debate REP and built cell-specific biological risk Kristen Fortney, CEO, BioAge Labs implementation? • With unprecedented data sharing via the cloud we have been provided with vast data lakes at our fingertips. networks Morten Sogaard, Vice President and Head, • Harnessing meaning from this data is possible through AI. • How UCSF employed this approach to Genome Sciences & Technologies, Worldwide R&D, • However, as AI advances we are unable to always disseminate why or how it has deduced meaning from the data. create individualized cell-specific risk Pfizer • With garbage in garbage out does AI become biased? networks to characterize risk in more than Chair: James Dzierzanowski, Executive Director, Kaiser Permanente 2000 patients John Havens, Executive Director, Global Initiative on Ethics of Autonomous and Intelligent Systems Sergio Baranzini, Professor, UCSF Greg Corrado, Co-founder, Google Brain Kay Firth-Butterfield, Head Artificial Intelligence and Machine Learning, World Economic Forum 4:00 MyGeneRank: A digital platform for Viome – our moonshot of creating a Programmable biology: Empowering the Next-Generation genetic studies world where chronic illness can truly Pocketome 6:30 Networking cocktail reception be a matter of choice • Building a fully digital ecosystem • The design and engineering of molecular, YOUNG TALENT IN AI AWARD 2018 for community-based participatory • Why human microbiome is influential if cellular and population-based computation genetics research: what are the societal not outright responsible for most chronic • Domain-specific languages for the To nominate yourself or a colleague for the Young Talent in AI Award, please contact Edward Glanville at +1 646 619 1713 or benefits and how could this inspire a diseases specification of biological computation [email protected] new generation of preventive health • Hear about thetechnology that enables • Theories and applications of biological Proposed by our partners in the field, this award will be presented to the most innovative and impressive example of AI research in BioData technology platforms? us to analyze microbial ecosystems, computation • Linking genetic + digital health data biochemical activities and immune system Riccardo Sabatini, Co-Founder, Chief Data 7:00 END OF CONFERENCE DAY ONE for health and behavioral insights and responses with AI and modulate these Officer, Orionis understanding how lifestyle factors affect activities with food and nutrition non-communicable diseases such as CHD • How exponential technologies are now • Implementing at-home diagnostics for making it possible for consumers to get those at high-risk of non-communicable insights into their bodies and act on them disease through combined genetic & to prevent and reverse chronic conditions health data to enable doctors to prescribe Naveen Jain, CEO, Viome and monitor patient centric personalized apps in realtime Ali Torkamani, Director of Genome Informatics, Drug Discovery, Integrative Structural & Computational Biology, The Scripps Translational Science Institute

4:20 Combining artificial intelligence and SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE collective intelligence to democratize Do you have a solution you would like to Do you have a solution you would like to bioinformatics share with our audience? share with our audience? • Designing the future of bioinformatics Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. thanks to the OMICtools community [email protected] or call at [email protected] or call at • How to find the right pipeline of tools +1 646.619.1809 +1 646.619.1809 thanks to AI-based decision-making solutions? • Making bioinformatics accessible without the need for advanced IT skills Arnaud Desfeu, Founder, omicX

4:40 Afternoon refreshments

5:10 PLATINUM SPONSORSHIP AVAILABLE Do you have a solution you would like to share with our audience? http://www.terrapinn.com/biodatawest Contact Michael Shackil now on: [email protected] or call at +1 646.619.1809 CONFERENCE DAY 2 1/4 CONFERENCE DAY 2 2/4

WEDNESDAY, MARCH 14TH 2018 WEDNESDAY, MARCH 14TH 2018

OPENING KEYNOTE PLENARY 11:00 How do you use metadata to unlock Collaborations with Industry to Brain Genomics and machine learning- the true potential of health data? accelerate rare disease discoveries in How to get a deep dive into the world the fastest way possible of brain genomics? 08:45 Producers opening remarks • Taming the stream of bytes- why disseminating data is not enough- How • How to structure relationships to protect • Review of the history and taxonomy of Edward Glanville, Project Director, Terrapinn tagging and curating maximizes the the interests of all parties when dealing machine learning and artificial intelligence capability of your data with rare diseases • Introducing deep learning- How is its 08:50 NASA GeneLab Project: using multi-omics to understand how space impacts life • New directions in data curation- how new • What are the required infrastructure to power increasing and how will it will • Inferring knowledge from diverse datasets using new NASA tools strategies have been developed out of make partnerships work? change the face of healthcare? • GeneLab data: factors influencing life in the space shuttle and the ISS including radiation and microgravity and what this means for humans back ICPSR to allow for easy accessibility and • Understanding the importance of • Concrete applications of AI to life sciences on earth retrieval of data phenotyping, transparency, and patient problems (calling SNP and indel variants • How to engage a larger community via higher order data and analysis working group • How metadata enhances discovery, use, engagement in next-generation sequencing data & • How to transfer the power of NASA based technologies into healthcare through collaborative efforts like NCI and NASA and preservation- maintenance of data is Catherine Brownstein, Scientific Director, detection of diabetic retinopathy from Sylvain Costes, Lead Scientist for GeneLab, NASA key – do you do enough? Manton Center for Orphan Disease Research fundus images of the eye) Amy Pienta, Associate Research Scientist, Mark DePristo, Head of Deep Learning for Director, Data Acquisitions, Director, National AIDS & Genomics and Genetics, Google Inc 09:00 Large Scale Deep Neural Networks to empower diagnostics and drug development: learnfrom the company at the bleeding HIV Data Archive Program, ICPSR edge of AI • Developing Google’s largest deep scale network – How do 16,000 computers studying 10 million images of cats help towards developing early 11:20 IT infrastructure to speed the delivery Biobanks - propelling precision Developing trials of the future diagnostics for disease? of Precision Medicine into the clinic medicine into the clinic in the fastest • How wearables are changing patient • Understand the power of deep neural networks and develop new targets and implement powerful deep learning networks to empower drug • How to develop an efficient network way possible centeredness and compliance for clinical discovery architecture to empower research across • Hear how Kaiser Permanente has trials • Open source tensor flow platforms -taking your drug development full steam through the world’s most powerful open AI chip your institution implemented precision medicine within its • Digital Biomarkers and Digital Greg Corrado, Co-founder, Google Brain • New requirements for the big data era are existing nationwide healthcare system Therapeutics: See how digitalization leads chancing - how are you preparing • How biobanks with research ready to better efficiency and insights 09:40 Developing the Inova Precision Medicine Roadmap: Convergence of implementation science, precision medicine, and the • Customized working environments:using biospecimens and associated EMR data • Developing large wearables trials - the learning healthcare system multi scenario prioritization to put the pave the way for the development of lessons learned from building arrhythmia • What are the challenges faced when implementing a system wide Precision Medicine platform across a healthcare system ? dollars back into the researcher’s pocket further physical tied to EMR databases data sets through wearables • Developing a harmonized roadmap for the implementation of precision medicine- Real world case studies on implementation of precision medicine and save computing power • How digitalization of biobanks allows Mintu Turakhia, Executive Director, Center for at Inova Jim Broach, Director of the Penn State Institute efficient access to specimens empowering Digital Health, Stanford University; Director, Cardiac Electrophysiology, Palo Alto VA • What were the financial implications and how can the model benefit your precision medicine implementation strategy? for Personalized Medicine, University of researchers to get what they need in the Pennsylvania School of Medicine fastest and efficient way possible • Collaborations and partnerships with vendors to make the process work How to make it a success story through developing early stage frameworks? Nazneen Aziz, Executive Director, Kaiser Permanente Research Bank Amit Rastogi, SVP for Strategy, Growth and Innovation, Inova 11:40 Developing an ecosystem in which EHR Rare Diseases and Precision Medicine Computational Drug Discovery using 10:00 PLATINUM SPONSORSHIP AVAILABLE and genomic data can flow freely • Accelerating development of novel Artificial Intelligence Do you have a solution you would like to share with our audience? • Elements of MVP (Million Veterans therapeutics through the transition of • Learn novel Deep Learning for design of Contact Michael Shackil now on: [email protected] or call at +1 646.619.1809 Program): the direction for the future, and genomic data into the AI based drug new molecules strategies to transform genomic efforts development • Benefits of AI for increasingly more 10:20 Morning refreshments into the clinic • Driving patient centricity through big data accurate property predictions • Building one of the world’s largest medical to drive cures to the patient in the fastest • Combining multi-modal data streams into GENOMICS AND HEALTH PRECISION MEDICINE ARTIFICIAL INTELLIGENCE databases by safely collecting blood way possible predictive modeling workflow samples and health information from one • Intercalating genomics and EHR records • ADME/Tox and off-target property million Veteran volunteers Data Infrastructure Rare Disease Text Mining and Image Recognition in an efficient and secure manner to drive optimization with AI methods • How to manipulate one of the largest forwards trail recruitment Olexandr Isayev, Professor, University Of genomic data sets in the world Mathew Pletcher, Head of Rare Disease 08:45 Chair: Ronald Przygodzki, Director, Genomic Chair: Catherine Brownstein, Scientific Chair: Mark DePristo, Head of deep learning North Carolina Discovery, Roche Medicine Implementation, VA Director, Manton Center for Orphan Disease for genetics and genomics, Google Inc • Future use of MVP data to enhance the Research health of veterans Ronald Przygodzki, Director, Genomic Medicine Implementation, VA

12:00 SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE Do you have a solution you would like to Do you have a solution you would like to Do you have a solution you would like to share with our audience? share with our audience? share with our audience? Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. http://www.terrapinn.com/biodatawest [email protected] or call at [email protected] or call at [email protected] or call at +1 646.619.1809 +1 646.619.1809 +1 646.619.1809 CONFERENCE DAY 2 4/4 CONFERENCE DAY 2 4/4

WEDNESDAY, MARCH 14TH 2018 WEDNESDAY, MARCH 14TH 2018

12:20 Networking Lunch 2:20 Understanding the power of Quantum Intermountain Precision Genomics for What would patients say if you asked Computing in Drug Discovery Everyday Patients them? Quantum Computing Technologies In The Clinic Translational Medicine • Using Quantum computing to transform • Developing efficient and rapid diagnostic • How patient experience is changing traditional R&D drug discovery processes, processes using WGS and gene panels the way pharma thinks about drug Chair: Karen Hurst, Chief Innovation Officer Chair: Matthew Nelson, President & Chief Chair: Christina Waters, President & Chief improve speed and productivity alongside • Comparing WGS and gene panels in areas development and Cyber, Moonshot Projects Executive Officer, GSK Executive Officer, R.A.R.E. Science significantly reducing costs and such as cost vs time implications and he • What patients can share with pharma: now accelerating access to new therapies for future of the technology and in the future patients 1:40 “Quantum Technology and Scaling real world collective Developing translational medicine • Navigating care pathways with the • What are the key lessons learnt from the QuantumBio” – an analysis intelligence through the three main pillars: • Unveiling a first-of-its-kind quantum- guidance of genomics data to provide frontline of patient engagement? enabled molecular comparison application • Hear the background and history of • Prediction: Gaining insights into new benchside, bedside and community economic value to institutions Julie Waters, Founder, Raremark that could significantly improve advanced quantum and how it relates to the future platforms to drive a new paradigm of AI • How to enable the transition of Pravin Mishra, Director, Precision Genomics Core molecular design to speed up drug of medicine • Precision: Develop a new understanding of knowledge between the three pillars of Laboratory & R&D, Intermountain Healthcare translation discovery for complex neurological • Understand the potential and the benefits the precision machine learning techniques conditions of quantum tech in healthcare? that empower precision. • Utilizing digital technologies to empower collaboration to accelerate research • Solving complex business problems • Who are the Discuss key research teams, • Prevention: Stabilizing patients before millions of times faster than classical vendors, technologies and the most symptomatic onsets • Understanding the educational road map computing by leveraging the properties of forward-thinking research? Thomas Clozel, Co-Founder, Owkin and processes across the translational quantum physics in computing Karen Hurst, Chief Innovation Officer and Cyber field Govinda Bhisetti, Head of Computational Security Analyst, Moonshot Projects Christina Waters, President & Chief Executive Chemistry, Biogen Officer, R.A.R.E. Science Ashley Winslow, Sr. Director, Translational 2:40 SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE SPONSORSHIP AVAILABLE Research & Portfolio Development, Orphan Disease Center, University of Pennsylvania Do you have a solution you would like to Do you have a solution you would like to Do you have a solution you would like to share with our audience? share with our audience? share with our audience? 2:00 Scalable quantum simulation of The genetics of drug efficacy: Tools to accelerate testing of new Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. Contact Michael Shackil now on: michael. molecular energies : Towards an exact opportunities and challenges Parkinson’s treatments by assisting in [email protected] or call at [email protected] or call at [email protected] or call at (quantum) description of chemistry • How efficacy has become the most trial design and subject stratification +1 646.619.1809 +1 646.619.1809 +1 646.619.1809 • Understanding the advantages of the common cause of attrition in late-phase • Identifying early clinical markers of rate of discipline in the acceleration of research drug development progression – how to benefit clinical care 3:00 Afternoon refreshments and testing of new therapies • How molecular energy functions can be • Driving the application of efficacy POST CONGRESS SHORT COURSES be defined by quantum computing faster pharmacogenetics into drug discovery and • Characterizing subgroups based on clinical than by classical models development across industry symptoms – how to allow trial sponsors to 3:40 test new therapies Data democratization and Precision medicine 101 Ai & quantum tools • Understand the advantages of quantum • Defining the value of routine, early usibility for your drug development process and and cumulative screening for genetic • Developing new avenues for • An overview of the clinical Round Table 1 Utilising Blockchain - Data security and ownership assess the impact on computing power predictors of efficacy, as an integrated investigations – how pathophysiology • Solving the dilemma of data appllications of genomic democratization: current medicine, skills to evaluate Round Table 2 Tensor Flow - Developing a greater understanding Ryan Babbush, Quantum Software Engineer component of clinical trial analysis can be targeted in a more efficient way of the chip and its possibilities methodologies for freeing data clinical validity and utility of new Google, Quantum A.I. Lab Matthew Nelson, Head of Genetics, GSK through AI from stasis tests, and the associated ethical Round Table 3 Hadoop- Developing new big data infrastructure Duygu Tosun-Turgut, Assistant Professor and social issues inherent to on a scalable level and Co-Director of the Center for Imaging of • Dollars vs Altruism: Utilizing novel Neurodegenerative Diseases (CIND), San Francisco technologies such as block chain genomics Round Table 4 Bayes DB- Understanding systems for Veterans Affairs Medical Center to provide a financial ecosystem • Conceptual and practical implementing AI for the layman to allow for data sharing information about real-world Round Table 5 Graph Databases - A short introduction applications of genomics • How to leverage usability of Round Table 6 Sequencing Populations- How to make it effective phenotypic and genotypic data Westyn Branch-Elliman, Instructor in and fast through computational efforts to Medicine, Harvard Medical School create a graphical database Round Table 7 AI in Drug Discovery- Partnering with new AI and tech companies Noel Burt, Program Manager, Broad Institute Round Table 8 Policy and Governance- Update on current legal Please visit the implications website for the Scott Brandon, Executive Director, Open Med Access Round Table 9 Aging and Drug Development- How investment in most up to date aging is becoming an essential topic agenda Round Table 10 Policy and Governance Round Table 11 Cancer Diagnostics- Liquid biopsies Round Table 12 Multimodel Integration- New AI methods

http://www.terrapinn.com/biodatawest 5:10 CONFERENCE ENDS SPONSORS & PARTNERS PRICING

It’s really easy to book your place online. And our online calculator will ensure you take advantage of the best deal.

Attending in a group? Check the website for discounted group passes!

Go to and book now on www.terrapinn.com/biodatawest

Package TIER 1 TIER 2 TIER 3 Final Price

2 day conference pass + $1,750 $1,800 $2,000 $2,500 Pre-Conference Workshop Day

2 day conference pass $1,400 $1,600 $1,800 $2,000

INTERESTED IN SPONSORING OR EXHIBITING? Contact Michael Shackil now at +1 646 619 1809 or [email protected]

http://www.terrapinn.com/biodatawest http://www.terrapinn.com/biodatawest